COVID-19 infection in a patient with multiple sclerosis treated with fingolimod

Neurol Neuroimmunol Neuroinflamm. 2020 May 5;7(4):e753. doi: 10.1212/NXI.0000000000000753. Print 2020 Jul.

¹ From the Department of Neurology (M.B., O.M., R.S., V.S.), School of Medicine, Isfahan University of Medical Sciences; Isfahan Neurosciences Research Center (M.B., O.M., N.N., V.S.), Isfahan University of Medical Sciences; Acquired Immunodeficiency Research Center (F.K.), Isfahan University of Medical Sciences, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
² From the Department of Neurology (M.B., O.M., R.S., V.S.), School of Medicine, Isfahan University of Medical Sciences; Isfahan Neurosciences Research Center (M.B., O.M., N.N., V.S.), Isfahan University of Medical Sciences; Acquired Immunodeficiency Research Center (F.K.), Isfahan University of Medical Sciences, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. [email protected].

No abstract available

Publication types